Will Shapiro, vice president of data science at Flatiron Health, explains the different ethical challenges associated with various forms of artificial intelligence models used in oncology care.
Ethical challenges in artificial intelligence (AI) models include regulatory oversight, authority, and bias, according to Will Shapiro, vice president of data science, Flatiron Health.
Transcript
What are some challenges around the proper use and ethics of AI in oncology?
I mean, there's a ton of challenges around using generative AI right now in practice. And absolutely, ethics and safety are hugely important considerations. I think it's an interesting time right now. In contrast to something like workflow automation or business intelligence—these are areas that have been around for a long time and that people kind of understand how to evaluate the quality and how to think about the outputs.
Generative AI is very early. When you see companies like OpenAI and Sam Altman [CEO of OpenAI] in particular, demanding and asking for regulators to come up with frameworks to think about the appropriate use of generative AI and guardrails, there's a lot to pay attention to.
Hallucinations are very real, and generative AI algorithms come from a place of technological authority. So, even if what they're saying is complete nonsense, it still has the sheen of authority. I think it's very pernicious.
And then, of course, with any machine learning or AI algorithm, bias is incredibly important to think about. GPT [generative pretrained transformer architecture] has already been demonstrated to be biased in several different ways. If we’re using these tools, we want to make sure that they make things better for everyone, not just for the select few, and don't perpetuate inequalities across health care.
For me, a lot of that comes down to having high-quality ground truth data that you trust and that you can use to validate the output of models against.
At Flatiron, we've been abstracting data from medical charts for a decade and are very proud of the labels that we have. What that gives us is an amazing way to validate the quality of ML [machine learning] models. So that's something I think a lot about and I’m very lucky to be able to work with that kind of label data.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More